| Literature DB >> 31564925 |
Maryam Haghighatpanah1, Ali Mojtahedi2.
Abstract
BACKGROUND: Urinary tract infections (UTIs) are one of the most frequent human infectious diseases causing considerable amount of morbidity and mortality. The present study aimed to investigate the occurrence of antibiotics resistance and virulence genes among Escherichia coli strains isolated from UTIs in the north of Iran.Entities:
Keywords: ESBL; Escherichia coli; antibiotics resistance; urinary tract infections; virulence factors
Year: 2019 PMID: 31564925 PMCID: PMC6731957 DOI: 10.2147/IDR.S219696
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
The sequences of used primers
| Target | Direction | Sequences (5ʹ to 3ʹ) | Function | Role | Ref. |
|---|---|---|---|---|---|
| F | AAGTCAAAGCAGGGGTTGCCCG | Siderophore receptor | Iron chelator | ||
| R | GACGCCGACATTAAGACGCAG | ||||
| F | TGATTAACCCCGCGACGGGAA | Ferric yersiniabactin uptake receptor | |||
| R | TGATTAACCCCGCGACGGGAA | ||||
| F | GGCTGGACATCATGGGAACTGG | Ferric aerobactin receptor | |||
| R | CGTCGGGAACGGGTAGAATCG | ||||
| F | ATGGCGCTAACTTGCCATGCTG | M blood group antigen-specific M fimbriae | Adhesin | ||
| R | AGGGGGACATATAGCCCCCTTC | ||||
| F | CTCCGGAGAACTGGGTGCATCTTAC | S fimbrial adhesins and F1C fimbriae | |||
| R | CGGAGGAGTAATTACAAACCTGGCA | ||||
| F | GTGGATACGACGATTACTGTG | S fimbrial adhesins | |||
| R | CCGCCAGCATTCCCTGTATTC | ||||
| F | CAGCACAGGCAGTGGATACGA | F1C fimbriae | |||
| R | GAATGTCGCCTGCCCATTGCT | ||||
| F | GGCAGAGGGCCGGCAACAGGC | Mannose-resistant | |||
| R | CCCGTAACGCGCCAGCATCTC | ||||
| F | GGGATGAGCGGGCCTTTGAT | Gal (alpha 1–4) Gal-binding adhesin molecules of P fimbriae | |||
| R | CGGGCCCCCAAGTAACTCG | ||||
| F | GGCCTGCAATGGATTTACCTGG | ||||
| R | CCACCAAATGACCATGCCAGAC | ||||
| F | TGCAGAACGGATAAGCCGTGG | Type 1 fimbrial adhesin | |||
| R | GCAGTCACCTGCCCTCCGGTA | ||||
| F | ATGGCAGTGGTGTCTTTTGGTG | P fimbrial | |||
| R | CGTCCCACCATACGTGCTCTTC | ||||
| F | GTGGCAGTATGAGTAATGACCGTTA | ||||
| R | ATATCCTTTCTGCAGGGATGCAATA | ||||
| F | GCAACAGCAACGCTGGTTGCATCAT | ||||
| R | AGAGAGAGCCACTCTTATACGGACA | ||||
| F | GCGCATTTGCTGATACTGTTG | Polysaccharide capsule | Protective | ||
| R | CATCCAGACGATAAGCATGAGCA | ||||
| F | ATCCATCAGGAGGGGACTGGA | O antigen polymerase | |||
| R | AACCATACCAACCAATGCGAG | ||||
| F | GGTGTGGTGCGATGAGCACAG | Anti-complementary protein of TraT | |||
| R | CACGGTTCAGCCATCCCTGAG | ||||
| F | ACATTCACGGCAAGCCTCAG | Uropathogenic-specific protein (genotoxin) | Invasion | ||
| R | AGCGAGTTCCTGGTGAAAGC | ||||
| F | AGGCAGGTGTGCGCCGCGTAC | Invasion of the brain endothelium protein A | |||
| R | TGGTGCTCCGGCAAACCATGC | ||||
| F | AAGATGGAGTTTCCTATGCAGGAG | Cytotoxic necrotizing factor-1 | |||
| R | CATTCAGAGTCCTGCCCTCATTATT | ||||
| F | AACAAGGATAAGCACTGTTCTGGCT | Hemolysin A | |||
| R | ACCATATAAGCGGTCATTCCCGTCA |
Distribution of antibiotic resistance pattern according to ESBL production
| Antibiotic | Total no. 129 | ESBLs-positive no. 66 | |||||
|---|---|---|---|---|---|---|---|
| Susceptible no. (%) | Intermediate no. (%) | Resistant no. (%) | Susceptible no. (%) | Intermediate no. (%) | Resistant no. (%) | ||
| Ampicillin | 24 (18.6) | 4 (3.1) | 101 (78.3) | 0 | 1 (1.5) | 65 (98.5) | <0.001 |
| Amoxicillin-clavulanate | 59 (45.7) | 43 (33.3) | 27 (20.9) | 15 (22.7) | 31 (47) | 20 (30.3) | <0.001 |
| Cefoxitin | 96 (74.4) | 13 (10.1) | 20 (15.5) | 37 (56.1) | 12 (18.2) | 17 (25.8) | <0.001 |
| Cefixime | 49 (38) | 9 (7) | 71 (55) | 1 (1.5) | 0 | 65 (98.5) | <0.001 |
| Ceftazidime | 51 (39.5) | 21 (16.3) | 57 (44.2) | 2 (3) | 9 (13.6) | 55 (83.3) | <0.001 |
| Ceftriaxone | 51 (39.5) | 5 (3.9) | 73 (56.6) | 1 (1.5) | 0 | 65 (98.5) | <0.001 |
| Cefotaxime | 43 (33.3) | 11 (8.5) | 75 (58.1) | 1 (1.5) | 0 | 65 (98.5) | <0.001 |
| Cefepime | 76 (58.9) | 7 (5.4) | 46 (35.7) | 17 (25.8) | 5 (7.6) | 44 (66.7) | <0.001 |
| Ciprofloxacin | 50 (38.8) | 10 (7.8) | 69 (53.5) | 7 (10.6) | 4 (6.1) | 55 (88.3) | <0.001 |
| Ofloxacin | 64 (49.6) | 0 | 65 (50.4) | 13 (19.7) | 0 | 53 (80.3) | <0.001 |
| Nalidixic acid | 27 (20.9) | 6 (4.7) | 96 (74.4) | 3 (4.5) | 0 | 63 (95.5) | <0.001 |
| Aztreonam | 56 (43.4) | 9 (7) | 64 (49.6) | 1 (1.5) | 5 (7.6) | 60 (90.9) | <0.001 |
| Tetracycline | 46 (35.7) | 3 (2.3) | 80 (62) | 13 (19.7) | 2 (3) | 51 (77.3) | <0.001 |
| Gentamicin | 84 (65.1) | 7 (5.4) | 38 (29.5) | 30 (45.5) | 2 (3) | 34 (51.5) | <0.001 |
| Trimethoprim/sulfamethoxazole | 38 (29.5) | 1 (0.8) | 90 (69.8) | 10 (15.2) | 0 | 56 (84.8) | <0.001 |
| Nitrofurantoin | 124 (96.1) | 3 (2.3) | 2 (1.6) | 63 (95.5) | 1 (1.5) | 2 (3) | 0.522 |
| Imipenem | 119 (92.2) | 10 (7.8) | 0 | 60 (90.9) | 6 (9.1) | 0 | 0.402 |
Distribution of virulence factors according to ESBL production
| Type | Gene | Total no. 129 | ESBLs-positive No. 66 | |||
|---|---|---|---|---|---|---|
| No. | % | No. | % | |||
| Iron chelator | 111 | 86 | 57 | 86.4 | 0.915 | |
| 32 | 24.8 | 19 | 28.8 | 0.284 | ||
| 75 | 58.1 | 38 | 57.6 | 0.894 | ||
| Adhesin | 35 | 27.1 | 23 | 34.8 | 0.044 | |
| 27 | 20.9 | 13 | 19.7 | 0.725 | ||
| 12 | 9.3 | 6 | 9.1 | 0.933 | ||
| 12 | 9.3 | 6 | 9.1 | 0.933 | ||
| 68 | 52.7 | 37 | 56.1 | 0.436 | ||
| 39 | 30.2 | 23 | 34.8 | 0.243 | ||
| 72 | 55.8 | 39 | 59.1 | 0.443 | ||
| 21 | 16.3 | 12 | 18.2 | 0.549 | ||
| 92 | 71.3 | 44 | 66.7 | 0.232 | ||
| 62 | 48.1 | 35 | 53 | 0.248 | ||
| 96 | 74.4 | 52 | 78.8 | 0.244 | ||
| Protective | 98 | 76 | 50 | 75.8 | 0.954 | |
| 4 | 3.1 | 1 | 1.5 | 0.288 | ||
| 113 | 87.6 | 59 | 89.4 | 0.526 | ||
| Invasion | 31 | 24 | 17 | 25.8 | 0.639 | |
| 39 | 30.2 | 23 | 34.8 | 0.243 | ||
| 88 | 68.2 | 47 | 71.2 | 0.455 | ||
| 44 | 34.1 | 26 | 39.4 | 0.195 | ||